Diiodohydroxyquinoline demonstrates a broad spectrum of bioactivities, indicating its potential as a versatile bioactive substance. It exhibits moderate to high potency as an inhibitor of various enzymes and pathways, including Lamin A Splicing, HSD17B4, JMJD2E, SMN2 Splice Variant Expression, TDP1, and ERK Signaling Pathway. Additionally, it shows potency in cell models for conditions such as Huntington's disease, Stat Signaling, Genomic imprint erasure, and Aldehyde Dehydrogenase 1 inhibition. Diiodohydroxyquinoline also affects cytotoxicity and cell viability in different cell lines, including HPDE-C7, HPDE-C7K, p53 mutant cancer cells, and during an influenza NS1 Protein Function assay.
Notably, it inhibits various protein functions such as 15-hLO, ROR gamma transcriptional activity, Menin-MLL Interaction, and Tyrosyl-DNA phosphodiesterase 1. The compound shows activity in inducing DNA re-replication, disrupting protein interactions, and inhibiting malarial parasite functions and cancer cells with p53 mutations. It also inhibits several kinases, including ERK1, ERK2, p38alpha, EGF Receptor, Fyn, ERBB2 (HER2), and LCK with varying IC50 values.
Moreover, Diiodohydroxyquinoline inhibits the OATP1B1 and OATP1B3 transporters, catechol-O-methyltransferase (COMT), and human BSEP. It shows antiviral activity against SARS-CoV-2 and antitrypanosomal activity against Trypanosoma brucei brucei. Additionally, it has antifungal activity against Candida albicans and Cryptococcus neoformans, antibacterial activity against Escherichia coli and other bacteria, and slight inhibition of human HDAC6 activity. The compound's solubility and permeability characteristics are suggested by its LogD7.4 value of 2.19, and it also shows haemolysis of human Red Blood Cells and cytotoxicity against HEK293 and HepG2 cells. Overall, Diiodohydroxyquinoline interacts with a variety of receptors and enzymes, suggesting its role as a multi-target bioactive compound..
Note: Summary generated by AI. Data source: ChEMBL 